Macro Dashboard
| Indicator | Level | 5-Day Change | Read |
|---|---|---|---|
| KOSPI | 5,683.8 | −4.3% | Bear |
| KOSDAQ | 715.0 | −5.1% | Bear |
| USD/KRW | 1,339 | −0.1% | Stable |
| VIX | 18.3 | +6.2% | Contained |
| Brent | $102.5 | −12.8% | Falling |
| US 10Y | 4.95% | −9 bp | Easing |
| DXY | 101.5 | −0.4% | Soft |
Regime: Korea — Bear (confirmed; only 18.5% of stocks above 50-day MA, Day 9 of downtrend signal). United States — Neutral (one of two required Bull confirmations cleared; NASDAQ and S&P 500 both above 200-day MA, VIX at 18.3).
Market Wrap
Today’s session delivered a broad surface recovery inside a deteriorating underlying structure. Of 2,591 issues tracked, 1,389 advanced and 933 declined, with an average daily return of +1.03% and an advance-decline ratio proxy of 148.9. That breadth reading suggests genuine width — not an index-only lift.
The character was rotational: EV batteries and renewables led; consumer and entertainment gave back ground. Samsung SDI (006400.KS) surged +11.57% with foreign and institutional buying arriving simultaneously — an alignment that rarely goes unnoticed. EcoPro (086520.KS, +9.54%) and EcoPro BM (247540.KS, +10.96%) attracted institutional flows alongside. Hanwha Solutions (009830.KS, +18.64%) drew strong institutional buying even as foreigners reduced exposure — a split signal to monitor. Korea Electric Power (015760.KS, +4.82%) and LG Uplus (032640.KS, +7.11%) also saw institutional accumulation, hinting at rotation toward rate-sensitive infrastructure names as the US 10-year yield eased nine basis points.
Weakness concentrated in entertainment and consumer. HYBE (352820.KS, −11.48%) saw simultaneous foreign and institutional selling. LG H&H (051900.KS, −11.83%) continued its retreat with institutions exiting. HLB (028300.KS, −17.69%) dropped sharply; foreigners bought the dip but institutions did not follow.
The flow structure underneath was less constructive. Program selling ran at −15,900 billion won — clearing the −15,000 billion threshold that flags directional institutional pressure — with futures basis at +0.60, below the +1.0 level needed to interpret program flows as supportive. ETF net creation of +10,623 billion won partially offset that pressure. The net picture: today’s advance was partly retail- and ETF-funded, while institutional directional selling continued in the background. The bear regime label stays intact.
Note: Same-day full close briefing was unavailable; this section is sourced from the KR Market Snapshot DB (2026-11-04).
Today’s Quality Re-Rating Candidates
The Meta Screener ranked 20 candidates from 101 tickers. Empirically-weighted scoring places consensus revision highest (+2.14×), followed by early RS leadership (+1.30×); fundamental quality and smart money signals carry 0.64× — meaningful but disciplined. Today produced no cross-screener overlap in the PEAD × Quality/Smart Money intersection, so the leading names come from the meta-ranked queue directly.
Top Candidates
| Rank | Ticker | Name | Families | Score | Screeners Hit | Key Signal |
|---|---|---|---|---|---|---|
| 1 | 011200.KS | HMM | 3 | 36.7 | Consensus Up, Quiet Accum, RS80 | Consensus z +0.54; retail −359B won absorbed by foreigners |
| 2 | 089860.KS | Lotte Rental | 3 | 36.0 | Cycle Rerating, Quiet Accum, RS80 | Margin +0.5pp; IR event today (DART); RS pivot gap +1.3% |
| 3 | 068270.KS | Celltrion | 3 families / 5 signals | 68.1 | Cycle, PEAD, RS80, SM Earnings, SM Quality | Margin +14.2pp; net F+QI +530B won; OP YoY +137% |
| 4 | 001120.KS | LX International | 2 | 33.5 | Quiet Accum, RS80 | Prelim earnings + IR value-up plan filed DART today |
| 5 | 089890.KQ | Coses | 2 | 30.0 | Consensus Up, Cycle Rerating | Margin +29.2pp; supply contract amendment ×2 on DART |
| 6 | 003160.KS | DI Corp | 2 | 21.8 | Consensus Up, Cycle Rerating | Margin +7.0pp; ⚠ F+QI net selling −203B won |
| 7 | 086450.KS | Dongkuk Pharm | 2 | 22.8 | PEAD, RS80 | OP YoY +20%; OPM 10.4%; RS 90th percentile |
| 8 | 128940.KS | HanmiPharm | 1 | 23.0 | Consensus Up | Consensus z +0.71; 6 DART catalysts incl. Fabry disease licensing |
Top 3 in Detail
#1 — HMM (011200.KS) Korea’s dominant container shipping operator. Three independent evidence families converge: analyst consensus revised upward (composite z +0.54), quiet accumulation detected foreign ownership rising in a compressed price band, and the RS80 not-late filter confirmed a 3.3% gap above pivot with a 20-day supply/flow score of +22.8%. The demand-side read is constructive — retail supplied −359B won that foreigners and quality institutions absorbed. Next check: whether the consensus revision reflects freight rate expectations or cost normalization, since the two imply different earnings durability.
#2 — Lotte Rental (089860.KS) Korea’s largest vehicle rental and fleet leasing operator. The cycle re-rating signal fired on a margin improvement of +0.5pp; quiet accumulation passed on foreign ownership rising in a tight price range; RS80 ranks it a Focus Candidate with box risk of −10.4% and a 20-day volume/flow score of +11.4%. Lotte Rental filed an IR event announcement on DART today (20261104) — same-day investor relations activity alongside screener signals is timing worth noting. Two risk-flagged DART filings are also present; reviewing their content matters before treating this setup as clean. Next check: DART risk filings and Q4 margin trajectory.
#3 — Celltrion (068270.KS) Korea’s leading biosimilar developer, now in commercial-stage expansion. Despite ranking third in the meta-screener, Celltrion carries the highest raw evidence density today — five signals across six independent families. The meta-ranker penalizes it slightly for the absence of a consensus revision signal, but the substance is hard to dismiss: cycle re-rating on +14.2pp margin expansion; PEAD Tier A with OP YoY +137% and revenue +17%; smart money quality confirmed with net foreign + quality-institution buying of +530B won as retail sold −1,025B won; smart money earnings also cleared; RS80 at a 7.4% premium to MA50. The key DART catalyst is a Phase 3 approval for CT-P13 SC (Zymfentra) in Europe for rheumatoid arthritis (filed 2026-11-02). Next check: European launch timeline and biosimilar pricing dynamics in the RA indication.
Sources: KR Meta Screener (2026-11-04), KR PEAD Screener (2026-11-04), Macro Regime Engine (2026-11-04), KR Market Snapshot DB (2026-11-04). Screener output is a research and editorial queue, not buy or sell guidance. All data provisional pending official close confirmation. DART filings available at dart.fss.or.kr.